Literature DB >> 31846439

Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.

Nimitha R Mathew1,2, Janaki M Vinnakota1,2,3, Petya Apostolova1,2,4, Daniel Erny4,5, Shaimaa Hamarsheh1,2, Geoffroy Andrieux6,7,8, Jung-Seok Kim9, Kathrin Hanke1,2, Tobias Goldmann5, Louise Chappell-Maor9, Nadia El-Khawanky1,2, Gabriele Ihorst1,2, Dominik Schmidt1,2, Justus Duyster1,2, Jürgen Finke1,2, Thomas Blank5, Melanie Boerries6,7,8, Bruce R Blazar10, Steffen Jung9, Marco Prinz5,11,12, Robert Zeiser1,2,11.   

Abstract

Acute graft-versus-host disease (GVHD) can affect the central nervous system (CNS). The role of microglia in CNS-GVHD remains undefined. In agreement with microglia activation, we found that profound morphological changes and MHC-II and CD80 upregulation occurred upon GVHD induction. RNA sequencing-based analysis of purified microglia obtained from mice with CNS-GVHD revealed TNF upregulation. Selective TNF gene deletion in microglia of Cx3cr1creER Tnffl/- mice reduced MHC-II expression and decreased CNS T cell infiltrates and VCAM-1+ endothelial cells. GVHD increased microglia TGF-β-activated kinase-1 (TAK1) activation and NF-κB/p38 MAPK signaling. Selective Tak1 deletion in microglia using Cx3cr1creER Tak1fl/fl mice resulted in reduced TNF production and microglial MHC-II and improved neurocognitive activity. Pharmacological TAK1 inhibition reduced TNF production and MHC-II expression by microglia, Th1 and Th17 T cell infiltrates, and VCAM-1+ endothelial cells and improved neurocognitive activity, without blocking graft-versus-leukemia effects. Consistent with these findings in mice, we observed increased activation and TNF production of microglia in the CNS of GVHD patients. In summary, we prove a role for microglia in CNS-GVHD, identify the TAK1/TNF/MHC-II axis as a mediator of CNS-GVHD, and provide a TAK1 inhibitor-based approach against GVHD-induced neurotoxicity.

Entities:  

Keywords:  Stem cell transplantation; Transplantation

Mesh:

Substances:

Year:  2020        PMID: 31846439      PMCID: PMC7269577          DOI: 10.1172/JCI130272

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Central nervous system graft-versus-host disease post allogeneic stem cell transplant.

Authors:  Jake Shortt; Elspeth Hutton; Mark Faragher; Andrew Spencer
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation.

Authors:  Ali G Saad; Edwin P Alyea; Patrick Y Wen; Umberto Degirolami; Santosh Kesari
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation.

Authors:  H Sakurai; H Miyoshi; W Toriumi; T Sugita
Journal:  J Biol Chem       Date:  1999-04-09       Impact factor: 5.157

4.  Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.

Authors:  Jan Hülsdünker; Katja J Ottmüller; Hannes P Neeff; Motoko Koyama; Zhan Gao; Oliver S Thomas; Marie Follo; Ali Al-Ahmad; Gabriele Prinz; Sandra Duquesne; Heide Dierbach; Susanne Kirschnek; Tim Lämmermann; Martin J Blaser; Brian T Fife; Bruce R Blazar; Andreas Beilhack; Geoffrey R Hill; Georg Häcker; Robert Zeiser
Journal:  Blood       Date:  2018-02-20       Impact factor: 22.113

5.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

6.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

7.  Target antigens determine graft-versus-host disease phenotype.

Authors:  Daniel H Kaplan; Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

8.  Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study.

Authors:  E R Unger; J H Sung; J C Manivel; M L Chenggis; B R Blazar; W Krivit
Journal:  J Neuropathol Exp Neurol       Date:  1993-09       Impact factor: 3.685

9.  A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells during Graft-versus-Host Disease.

Authors:  Verena Klämbt; Sebastian A Wohlfeil; Lukas Schwab; Jan Hülsdünker; Korcan Ayata; Petya Apostolova; Annette Schmitt-Graeff; Heide Dierbach; Gabriele Prinz; Marie Follo; Marco Prinz; Marco Idzko; Robert Zeiser
Journal:  J Immunol       Date:  2015-11-04       Impact factor: 5.422

10.  Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation.

Authors:  Yochai Wolf; Anat Shemer; Michal Polonsky; Mor Gross; Alexander Mildner; Simon Yona; Eyal David; Ki-Wook Kim; Tobias Goldmann; Ido Amit; Mathias Heikenwalder; Sergei Nedospasov; Marco Prinz; Nir Friedman; Steffen Jung
Journal:  J Exp Med       Date:  2017-03-22       Impact factor: 14.307

View more
  14 in total

Review 1.  Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Authors:  Geoffrey D E Cuvelier; Michelle Schoettler; Nataliya P Buxbaum; Iago Pinal-Fernandez; Marc Schmalzing; Jörg H W Distler; Olaf Penack; Bianca D Santomasso; Robert Zeiser; Klemens Angstwurm; Kelli P A MacDonald; W Taylor Kimberly; Naomi Taylor; Ervina Bilic; Bernhard Banas; Maike Buettner-Herold; Namita Sinha; Hildegard T Greinix; Joseph Pidala; Kirk R Schultz; Kirsten M Williams; Yoshihiro Inamoto; Corey Cutler; Linda M Griffith; Stephanie J Lee; Stefanie Sarantopoulos; Steven Z Pavletic; Daniel Wolff
Journal:  Transplant Cell Ther       Date:  2022-05-31

2.  Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Marie Czech; Robert Zeiser; Tomomi Toubai
Journal:  Front Immunol       Date:  2022-06-08       Impact factor: 8.786

3.  Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series.

Authors:  Michele Wieczorek; Sara Mariotto; Sergio Ferrari; Federico Mosna; Maria Caterina Micò; Carlo Borghero; Maria Vittoria Dubbini; Michele Malagola; Cristina Skert; Angelo Andreini; Beatrice De Marco; Diana Polo; Ahmad Tfaily; Mauro Krampera; Anna Grassi; Anna Candoni; Federica Ranzato; Irene Volonghi; Rocco Quatrale; Fabio Benedetti; Cristina Tecchio
Journal:  Bone Marrow Transplant       Date:  2022-05-05       Impact factor: 5.174

4.  Different effects of constitutive and induced microbiota modulation on microglia in a mouse model of Alzheimer's disease.

Authors:  Charlotte Mezö; Nikolaos Dokalis; Omar Mossad; Ori Staszewski; Jana Neuber; Bahtiyar Yilmaz; Daniel Schnepf; Mercedes Gomez de Agüero; Stephanie C Ganal-Vonarburg; Andrew J Macpherson; Melanie Meyer-Luehmann; Peter Staeheli; Thomas Blank; Marco Prinz; Daniel Erny
Journal:  Acta Neuropathol Commun       Date:  2020-07-29       Impact factor: 7.801

Review 5.  Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Hemasphere       Date:  2021-06-01

6.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10

Review 7.  Essential Role of Complement in Pregnancy: From Implantation to Parturition and Beyond.

Authors:  Guillermina Girardi; Joshua J Lingo; Sherry D Fleming; Jean F Regal
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

Review 8.  How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Benoît Vandenhove; Lorenzo Canti; Hélène Schoemans; Yves Beguin; Frédéric Baron; Carlos Graux; Tessa Kerre; Sophie Servais
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

Review 9.  Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sophia Chen; Robert Zeiser
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

10.  MiR-367 alleviates inflammatory injury of microglia by promoting M2 polarization via targeting CEBPA.

Authors:  Hui Pei; Qian Peng; Shewei Guo; Yulei Gu; Tongwen Sun; Dong Xu; Yumin Jiang; Jiafeng Xie; Luanluan Zhang; Zhiqiang Zhu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2020-11-04       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.